An observational study in Dry Age-related Macular Degeneration, Geographic Atrophy and Retinal Disease, sponsored by Complement Therapeutics. Completed at 22 sites in 2 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Complement Therapeutics · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Geographic Atrophy with a site in United Kingdom — 13 open to participants now, 17 under way, 4 of them phase 3. Geographic Atrophy · United Kingdom.
Among the 38 studies in Geographic Atrophy with a site in United Kingdom, this one is one of 3 that started in 2023, is one of 8 observational ones, and was the 23rd registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →13 of the 38 studies in Geographic Atrophy with a site in United Kingdom are open now. Recruiting first, the newest first:
Sitala Bio LTD · Sites in United Kingdom, United States, Argentina and 4 more countries
Ages 60+
Novartis Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 16 more countries
Ages 50+
Complement Therapeutics · Sites in United Kingdom, United States
Ages 55+
ADARx Pharmaceuticals, Inc. · Sites in United Kingdom, United States, Australia and 9 more countries
Ages 60+
ONL Therapeutics · Sites in United Kingdom, United States, Austria and 9 more countries
Ages 55+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.
This study: 65 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 12 · Phase 4 1
First in 2014; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 234 is above the median of 130 across 39 observational studies indexed under Geographic Atrophy.
Median enrollment 303 across the 30 interventional studies, 201 across the 8 observational. Of the 21 that completed or were terminated, 14 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 38 have an industry lead sponsor. The 10 most frequent:
Complement Therapeutics is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Complement Therapeutics has 3 studies filed under Geographic Atrophy — fewer than ten, so there is no comparison to draw.
7 of the studies in Geographic Atrophy with a site in United Kingdom that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05949593Phase 3Belite Bio, IncPhase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | 2027-06-30 |
| NCT06510816Phase 3Annexon, Inc.A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) | 2027-07-31 |
| NCT07144137Complement TherapeuticsA Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA) | 2027-03-31 |
| NCT06662162i-Lumen Scientific AUS PTY LTDMicrocurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration | 2027-03-31 |
| NCT04796545VisionCare, Inc.Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration | 2027-05 |
Add all 7 to your calendar (.ics) → With an account.
Among the 38 studies in Geographic Atrophy with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An observational study to investigate the natural history and evaluate biomarkers of participants with geographic atrophy secondary to age-related macular degeneration
Prospective, observational study to assess the relationships between circulating levels of complement proteins measured using the Complement Precision Medicine (CPM) Platform, genetic profile and lesion progression in subjects with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD) up to a 24-month period
Approximately 250 participants, age 65 years and older, with bilateral GA due to AMD will be accrued.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levels of complement proteins
To assess the correlation between circulating levels of complement proteins measured using the Complement Precision Medicine (CPM) Platform and Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD)
Time frame: Month 6, 12,18, 24
Geographic Atrophy
To investigate whether there is a relationship between progression of GA and complement profile measured using the CPM platform
Time frame: Up to 24 months
Genetics
To investigate the relationship between variants in genes or loci associated with AMD and the complement profile measured using the CPM platform
Time frame: Up to 24 months
Complement Proteins Intra-individual Variation
To determine the intra-individual variation in complement profile using the Complement Precision Medicine (CPM) Platform, in participants with GA
Time frame: Up to 24 months
Complement Proteins and Progression of GA
To investigate whether there is a relationship between progression of GA and complement profile measured using the Complement Precision Medicine (CPM) platform
Time frame: Up to 24 months
Choroidal Blood Flow and Genetics
To investigate the relationship in genes or loci associated with AMD and choroidal blood flow and structure
Time frame: Up to 24 months
Choroidal Blood Flow and GA Lesion Progression
To investigate the relationships between choroidal blood flow and structure and GA lesion progression
Time frame: Up to 24 months
CRP Levels
To observe the influence of any past or concurrent illnesses, in particular inflammation-related illnesses, rise in serum CRP or of any medications on complement profile using the CPM Platform
Time frame: Up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Feb 2023 to primary completion in Dec 2025, 34 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Jul 2027 → Dec 2025 and completion Jul 2027 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Complement Therapeutics